Home › Funds › Lynx1 Capital Management LP › CGEM

Lynx1 Capital Management LP position in CGEM

CULLINAN THERAPEUTICS INC · Health Care

Lynx1 Capital Management LP reported holding 8,963,500 shares of CGEM (CULLINAN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$163.2M, representing 18.86% of its reported portfolio and ranking #2 among its reported holdings. Lynx1 Capital Management LP has disclosed CGEM holdings in 9 of the last 9 reported quarters, going back to Q2 2024.

Latest position (Q2 2026)8.96M sh
Reported value held$163.23M
Portfolio Weight18.86%
First reportedQ2 2024
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Lynx1 Capital Management LP's CGEM position evolved

Lynx1 Capital Management LP first disclosed a stake in CGEM in Q2 2024 at 377,323 shares (US$6.6M). The position peaked in Q2 2026 at 8,963,500 shares, worth US$163.2M. Across 9 filings, Lynx1 Capital Management LP increased the stake 6 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 8,963,500 shares valued at US$163.2M. Notable position changes include a 206% increase in Q4 2024 (shares fell 38% over the following quarter), a 156% increase in Q1 2025 (shares were roughly flat over the following quarter), a 55% increase in Q4 2025 (shares rose 37% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 377.32K $6.58M New
Q3 2024 410.83K $6.88M Add
Q4 2024 1.26M $15.32M Add
Q1 2025 3.22M $24.34M Add
Q2 2025 4.40M $33.14M Add
Q3 2025 5.77M $34.19M Add
Q4 2025 8.96M $92.77M Add
Q1 2026 8.96M $127.37M Hold
Q2 2026 8.96M $163.23M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CGEM and 13F data

CGEM (CULLINAN THERAPEUTICS INC) is a Health Care company. 37 other funds we track also report a position in CGEM — the largest reported positions include MPM BioImpact LLC (US$177.2M), BVF INC/IL (US$104.7M), Kynam Capital Management, LP (US$56.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CGEM

All CGEM fund holders →

FAQ

How long has Lynx1 Capital Management LP held CGEM?

Lynx1 Capital Management LP has disclosed CGEM holdings in 9 of the last 9 reported quarters, going back to Q2 2024.

What is Lynx1 Capital Management LP's current position in CGEM?

As of Q2 2026, Lynx1 Capital Management LP holds 8.96M shares of CGEM (CULLINAN THERAPEUTICS INC), valued at $163.23M, representing 18.86% of its reported portfolio and ranking #2.

Has Lynx1 Capital Management LP been buying or selling CGEM?

In the latest 13F filing (Q2 2026), Lynx1 Capital Management LP held unchanged its position in CGEM. The position peaked in Q2 2026 at 8.96M shares.

Which other funds hold CGEM?

Other major institutional holders of CGEM include MPM BioImpact LLC, BVF INC/IL, Kynam Capital Management, LP, among 37 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.